Axsome Therapeutics Unveils New Data Across Psychiatry and Neurology Portfolio at Psych Congress 2026
Event summary
- Axsome Therapeutics presented ten posters at Psych Congress 2026, showcasing data on major depressive disorder, Alzheimer’s disease agitation, and narcolepsy.
- Presentations included real-world treatment patterns, clinical outcomes, and patient quality of life studies.
- Key focus areas were dextromethorphan-bupropion for major depressive disorder and solriamfetol for excessive daytime sleepiness.
- Posters were displayed from September 17 to 18, 2026, in New Orleans, Louisiana.
The big picture
Axsome Therapeutics is reinforcing its position in the CNS therapy space by highlighting real-world clinical outcomes and patient quality of life improvements. The data presented at Psych Congress 2026 could bolster its market differentiation, particularly in major depressive disorder and Alzheimer’s disease agitation, where treatment gaps remain significant. The company’s focus on novel mechanisms of action aligns with broader industry trends toward personalized and targeted CNS therapies.
What we're watching
- Clinical Validation
- How the new data will influence the adoption of Axsome’s treatments in major depressive disorder and Alzheimer’s disease agitation.
- Regulatory Pathways
- Whether the real-world evidence presented will support additional FDA approvals or label expansions for Axsome’s products.
- Market Differentiation
- The pace at which Axsome can differentiate its portfolio in the competitive CNS therapy landscape.